Fluxapyroxad disrupt erythropoiesis in zebrafish (Danio rerio) embryos br

Fluxapyroxad, a succinate dehydrogenase inhibitor (SDHI) fungicide, is commercialized worldwide to control a variety of fungal diseases. Growing evidence shows that fluxapyroxad is teratogenic to aquatic organisms. In this study, the influence of fluxapyroxad toward hematopoietic development was evaluated using zebrafish embryos which were exposed to fluxapyroxad (0.03 mu M, 0.3 mu M and 3 mu M) from 3 h post fertilization (hpf) to 3 days post fertilization (dpf). Compared to the control groups, the hemoglobin was ectopic and decreased in response to fluxapyroxad treatment. The transcription levels of genes (hbbe1, hbbe2, and gata1a) involved in erythropoiesis were reduced after exposure to fluxapyroxad. In contrast, the distributions and expression of marker genes for myeloid lineage cells were unaffected by fluxapyroxad exposure. Our data suggested that fluxapyroxad might specifically affect erythropoiesis and hold great promise for the assessment of the toxicity of fluxapyroxad to aquatic organisms.

Automated summary

In this study, the influence of fluxapyroxad on hematopoietic development was evaluated using zebrafish embryos. The results showed that fluxapyroxad treatment led to abnormal distribution and decreased levels of hemoglobin, as well as reduced transcription levels of genes involved in erythropoiesis.